Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP
Fresenius Kabi announced today the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT.
- Fresenius Kabi announced today the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT.
- Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
- Fresenius Kabi produces Lacosamide Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems.
- Fresenius Kabi Lacosamide Injection for intravenous use (CV) is indicated for the treatment of partial-onset seizures in patients 17 years of age and older.